115956-12-2
Chemical Structure
Dolasetron
Synonym(s): MDL-73147
- CAS No.: 115956-12-2
- Formula:C19H20N2O3
- Molecular Weight:324.37
IUPAC Name: (5s,6R,8r,9aS)-3-oxooctahydro-2H-2,6-methanoquinolizin-8-yl 1H-indole-3-carboxylate
InChIKey: UKTAZPQNNNJVKR-MMUVGSQPSA-N
SMILES: O=C(C1=CNC2=C1C=CC=C2)O[C@@H]3C[C@@](CC4C5)([H])[N@](CC4=O)[C@@]5([H])C3
Biological Activity: Dolasetron (MDL-73147) is a serotonin 5-HT3 receptor antagonist. Dolasetron acts as an antiemetics agent and can be used for the research of chemotherapy-induced nausea and vomiting in cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dolasetron | 99.90% | Dolasetron (MDL-73147) is a serotonin 5-HT3 receptor antagonist. Dolasetron acts as an antiemetics agent and can be used for the research of chemotherapy-induced nausea and vomiting in cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dolasetron-d5 | Dolasetron (MDL-73147)-d5 is deuterated labeled Dolasetron (HY-B0750). Dolasetron is a serotonin 5-HT3 receptor antagonist. Dolasetron acts as an antiemetics agent and can be used for the research of chemotherapy-induced nausea and vomiting in cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dolasetron-d4 | Dolasetron (MDL-73147)-d4 is deuterium labeled Dolasetron (HY-B0750). Dolasetron is a serotonin 5-HT3 receptor antagonist. Dolasetron acts as an antiemetics agent and can be used for the research of chemotherapy-induced nausea and vomiting in cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Faria C, et al. Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis. Am Health Drug Benefits. 2014;7(1):50-58. [Content Brief]
- [2]. Schwartzberg L, et al. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer. 2014;22(2):469-477. [Content Brief]
Keywords